Secukinumab eases psoriatic arthritis across disease spectrum

Patients saw greatest benefits after 16 weeks on 300mg, according to industry-funded study

Many patients with psoriatic arthritis treated with secukinumab have reduced symptoms and improved quality of life compared with placebo, according to an industry-funded study of more than 2000 patients. 

Psoriatic arthritis

The posthoc analysis used data from patients with psoriatic arthritis participating in four on-label phase three trials.

US researchers used the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and Outcome Measures in Rheumatology (GRAPPA-OMERACT) to measure improvements in a range of domains, including